Apellis Pharmaceuticals saw a welcome improvement to its Relative Strength (RS) Rating on Tuesday, with an upgrade from 66 to 74.
When looking for the best stocks to buy and watch, one factor to watch closely is relative price strength.
This exclusive rating from Investor's Business Daily identifies price performance with a 1 (worst) to 99 (best) score. The rating shows how a stock's price movement over the trailing 52 weeks holds up against all the other stocks in our database.
Over 100 years of market history shows that the best stocks typically have an RS Rating north of 80 as they begin their biggest price moves. See if Apellis Pharmaceuticals can continue to show renewed price strength and hit that benchmark.
Looking For Winning Stocks? Try This Simple Routine
Apellis Pharmaceuticals is not currently near a potential buy zone. The stock fell hard a few months ago. See if the stock goes on to form a promising consolidation that could ignite a new run.
APLS Earnings
The company posted 0% EPS growth last quarter. Revenue rose 482%. Look for the next report on or around Nov. 6.
The company holds the No. 110 rank among its peers in the Medical-Biomed/Biotech industry group. Vertex Pharmaceuticals and HUTCHMED (China) ADR are also among the group's highest-rated stocks.
Stocks To Buy And Watch: Top IPOs, Big And Small Caps, Growth Stocks
